Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Neuropace Inc's Business Segments
Neuropace Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Non-US
Total Revenue
$ 23
Regions Reported
1
Revenue Share by Reportable Segment - FY
- Non-US4.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 1 | 4.8% |
Revenue Share by Region - FY
- Non-US3.2%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 1 | 3.2% |
Annual Results
Revenue Share by Reportable Segment - FY
- Non-US4.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 1 | 4.8% |
Description of Neuropace Inc
Neuropace Inc is a medical device company that specializes in developing and manufacturing neurostimulation systems for the treatment of neurological disorders. The company was founded in 1997 by David Fischell, a renowned biomedical engineer, with the goal of providing innovative solutions for patients with intractable epilepsy.
The flagship product of Neuropace Inc is the RNS System, which stands for Responsive Neurostimulation System. This implantable device is designed to monitor and respond to brain activity in order to prevent epileptic seizures. It consists of a small neurostimulator, which is implanted under the scalp, and leads that are placed on or within the brain, near the seizure focus. The RNS System continuously monitors the brain's electrical activity and delivers electrical stimulation to disrupt abnormal activity and prevent seizures from occurring.
The RNS System incorporates advanced technology, including a closed-loop system that adapts its stimulation parameters based on real-time brain activity. It uses sophisticated algorithms to detect and analyze patterns associated with seizure onset, allowing for personalized treatment tailored to each patient's needs. The device can also collect long-term data on brain activity, providing valuable insights into the patient's condition and treatment effectiveness.
Neuropace Inc has conducted extensive clinical trials to evaluate the safety and efficacy of the RNS System. The data from these trials have demonstrated significant reductions in seizure frequency and improvements in quality of life for patients with drug-resistant epilepsy. The RNS System has received regulatory approvals in the United States and Europe, making it available to patients in these regions.
In addition to its focus on epilepsy, Neuropace Inc is also exploring the potential of its neurostimulation technology for other neurological conditions. The company is actively involved in research and development efforts to expand the applications of the RNS System and provide new solutions for patients with various brain disorders.
Neuropace Inc is headquartered in Mountain View, California and has a dedicated team of researchers, engineers, and healthcare professionals working towards advancing the field of neuromodulation. The company maintains collaborations with leading academic institutions and medical centers to foster innovation and ensure the development of cutting-edge solutions for patients.
Overall, Neuropace Inc is a pioneering company in the field of neurostimulation, dedicated to improving the lives of individuals with neurological disorders through innovative medical devices and personalized treatment approaches. With its flagship product, the RNS System, the company has established itself as a leader in the emerging field of responsive neurostimulation.
The flagship product of Neuropace Inc is the RNS System, which stands for Responsive Neurostimulation System. This implantable device is designed to monitor and respond to brain activity in order to prevent epileptic seizures. It consists of a small neurostimulator, which is implanted under the scalp, and leads that are placed on or within the brain, near the seizure focus. The RNS System continuously monitors the brain's electrical activity and delivers electrical stimulation to disrupt abnormal activity and prevent seizures from occurring.
The RNS System incorporates advanced technology, including a closed-loop system that adapts its stimulation parameters based on real-time brain activity. It uses sophisticated algorithms to detect and analyze patterns associated with seizure onset, allowing for personalized treatment tailored to each patient's needs. The device can also collect long-term data on brain activity, providing valuable insights into the patient's condition and treatment effectiveness.
Neuropace Inc has conducted extensive clinical trials to evaluate the safety and efficacy of the RNS System. The data from these trials have demonstrated significant reductions in seizure frequency and improvements in quality of life for patients with drug-resistant epilepsy. The RNS System has received regulatory approvals in the United States and Europe, making it available to patients in these regions.
In addition to its focus on epilepsy, Neuropace Inc is also exploring the potential of its neurostimulation technology for other neurological conditions. The company is actively involved in research and development efforts to expand the applications of the RNS System and provide new solutions for patients with various brain disorders.
Neuropace Inc is headquartered in Mountain View, California and has a dedicated team of researchers, engineers, and healthcare professionals working towards advancing the field of neuromodulation. The company maintains collaborations with leading academic institutions and medical centers to foster innovation and ensure the development of cutting-edge solutions for patients.
Overall, Neuropace Inc is a pioneering company in the field of neurostimulation, dedicated to improving the lives of individuals with neurological disorders through innovative medical devices and personalized treatment approaches. With its flagship product, the RNS System, the company has established itself as a leader in the emerging field of responsive neurostimulation.
NeuroPace Inc. is a medical technology company primarily focused on developing innovative solutions for treating neurological disorders, particularly epilepsy. Their flagship product is a responsive neurostimulation device, which represents a significant advancement in the field of neuromodulation. Here’s a detailed look at the segments, products, and services offered by NeuroPace:
Segments
1. Medical Devices for Neurology
- NeuroPace operates within the broader medical device industry, focusing specifically on neurology. This segment is dedicated to the development and commercialization of devices that address neurological conditions, including epilepsy and other related disorders.
2. Patient Care and Management
- NeuroPace also emphasizes the importance of care management for patients with neurological disorders. This segment focuses on providing ongoing support and monitoring for individuals using their devices, ensuring optimal care and treatment pathways.
3. Clinical Research and Development
- The company is heavily invested in R&D, working on improving existing technologies and potentially exploring new applications in neuromodulation and neurostimulation for other neurological or psychiatric disorders.
Products
1. RNS® System
- The Responsive Neurostimulation (RNS®) System is NeuroPace’s primary product. It is an implanted device designed for patients with drug-resistant epilepsy. The system monitors electrical brain activity and delivers targeted stimulation to prevent seizures. Key components of the RNS System include:
- Implantable Neurostimulator: This small device is placed in the skull and connected to electrodes implanted in the brain to monitor electrical activity.
- Electrodes: These are implanted in the regions of the brain identified as the source of seizures, allowing precise monitoring and stimulation.
- Patient Controller: A handheld device that allows patients to interact with the RNS system, including recording seizure activity and adjusting settings as directed by their healthcare providers.
2. Data Management Software
- NeuroPace provides software solutions that facilitate patient monitoring and data collection. These tools help clinicians track patient progress, adjust treatment protocols, and gain insights into seizure patterns and triggers through data analysis.
Services
1. Patient Support Programs
- NeuroPace offers comprehensive support programs for patients who receive the RNS System. This includes educational resources about the device, how it works, and what to expect during and after the implantation process. The goal is to provide patients with the knowledge needed to manage their condition effectively.
2. Clinical Training and Support for Healthcare Providers
- The company provides training and ongoing education for healthcare professionals involved in the implantation and management of the RNS System. By offering resources ranging from technical training to best practices in patient management, NeuroPace ensures that clinicians are well-equipped to utilize their technology effectively.
3. Clinical Trials and Research Collaborations
- NeuroPace actively engages in clinical trials to gather data on the efficacy of their products and explore new applications in neuromodulation. They often collaborate with academic institutions and other research organizations to further investigate the efficacy and safety of their technology.
4. Telehealth Solutions
- With the rise of telemedicine, NeuroPace is likely to incorporate telehealth solutions that facilitate remote monitoring and consultations, enhancing convenience and accessibility for patients with epilepsy.
Future Directions
While NeuroPaces current emphasis remains on epilepsy, there is potential for the company to explore applications for other neurological disorders, such as depression, Parkinson’s disease, and other conditions that may benefit from neuromodulation techniques. As they continue to gather data from ongoing clinical usage and trials, the company may refine their products and services to address broader markets within neurology.
In summary, NeuroPace Inc. operates at the intersection of medical technology and neurological care, primarily focusing on responsive neurostimulation for epilepsy but also positioning itself for broader applications in the future. Its commitment to patient care and clinical support underscores the companys dedication to advancing treatment options in the field of neurology.
Segments
1. Medical Devices for Neurology
- NeuroPace operates within the broader medical device industry, focusing specifically on neurology. This segment is dedicated to the development and commercialization of devices that address neurological conditions, including epilepsy and other related disorders.
2. Patient Care and Management
- NeuroPace also emphasizes the importance of care management for patients with neurological disorders. This segment focuses on providing ongoing support and monitoring for individuals using their devices, ensuring optimal care and treatment pathways.
3. Clinical Research and Development
- The company is heavily invested in R&D, working on improving existing technologies and potentially exploring new applications in neuromodulation and neurostimulation for other neurological or psychiatric disorders.
Products
1. RNS® System
- The Responsive Neurostimulation (RNS®) System is NeuroPace’s primary product. It is an implanted device designed for patients with drug-resistant epilepsy. The system monitors electrical brain activity and delivers targeted stimulation to prevent seizures. Key components of the RNS System include:
- Implantable Neurostimulator: This small device is placed in the skull and connected to electrodes implanted in the brain to monitor electrical activity.
- Electrodes: These are implanted in the regions of the brain identified as the source of seizures, allowing precise monitoring and stimulation.
- Patient Controller: A handheld device that allows patients to interact with the RNS system, including recording seizure activity and adjusting settings as directed by their healthcare providers.
2. Data Management Software
- NeuroPace provides software solutions that facilitate patient monitoring and data collection. These tools help clinicians track patient progress, adjust treatment protocols, and gain insights into seizure patterns and triggers through data analysis.
Services
1. Patient Support Programs
- NeuroPace offers comprehensive support programs for patients who receive the RNS System. This includes educational resources about the device, how it works, and what to expect during and after the implantation process. The goal is to provide patients with the knowledge needed to manage their condition effectively.
2. Clinical Training and Support for Healthcare Providers
- The company provides training and ongoing education for healthcare professionals involved in the implantation and management of the RNS System. By offering resources ranging from technical training to best practices in patient management, NeuroPace ensures that clinicians are well-equipped to utilize their technology effectively.
3. Clinical Trials and Research Collaborations
- NeuroPace actively engages in clinical trials to gather data on the efficacy of their products and explore new applications in neuromodulation. They often collaborate with academic institutions and other research organizations to further investigate the efficacy and safety of their technology.
4. Telehealth Solutions
- With the rise of telemedicine, NeuroPace is likely to incorporate telehealth solutions that facilitate remote monitoring and consultations, enhancing convenience and accessibility for patients with epilepsy.
Future Directions
While NeuroPaces current emphasis remains on epilepsy, there is potential for the company to explore applications for other neurological disorders, such as depression, Parkinson’s disease, and other conditions that may benefit from neuromodulation techniques. As they continue to gather data from ongoing clinical usage and trials, the company may refine their products and services to address broader markets within neurology.
In summary, NeuroPace Inc. operates at the intersection of medical technology and neurological care, primarily focusing on responsive neurostimulation for epilepsy but also positioning itself for broader applications in the future. Its commitment to patient care and clinical support underscores the companys dedication to advancing treatment options in the field of neurology.